Some analysts say Eli Lilly’s daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors.
In the trial, orforglipron caused weight loss that missed Wall Street’s expectations and came below what Novo Nordisk reported for its oral drug in a separate study.
But Eli Lilly’s drug could have a few advantages over Novo Nordisk’s pill, including a lack of dietary restrictions, easier manufacturing and a potentially lower price, according to some analysts.
I do think it could end up being extremely popular, depending on tolerability and cost/access, since so many people prefer pills to injections and being able to take it with food is a big bonus.
It also might have a place for long-term maintenance (lose weight fast with retatrutide, for instance, then switch to orfo to keep it off). Also for those who want a less aggressive therapy to lose 10 or 15 pounds of fat to look better and be healthier.
Semaglutide is going generic in India in a week. Has anyone had any success getting a quote for generic tablets? I asked Maulik but he said he hasn’t got any info yet.
Sadly, these injection drugs like ozempic need to be refrigerated, so its not going to be very feasible to import these from India (shipping times frequently take a few weeks, so its going to degrade the product).
The patent exclusivity for Rybelsus (oral semaglutide) is highly fragmented by jurisdiction, governed by a complex intersection of core compound patents, regulatory extensions, and secondary formulation patents.
India
Expiration Date:March 20, 2026
Status: The core compound patent protecting semaglutide has officially expired in India. Because India does not grant patent term extensions for regulatory delays, Novo Nordisk lost exclusivity precisely 20 years after the initial 2006 international patent filing. Over 40 domestic pharmaceutical companies are currently launching generic equivalents, driving rapid price depreciation and vastly expanding market access. Source: Fierce Pharma
Canada
Expiration Date:January 4, 2026
Status: Canada operates as a unique anomaly among G7 nations regarding semaglutide exclusivity. Novo Nordisk’s data exclusivity and core patent protections lapsed in early January 2026 due to the company not pursuing or failing to secure further patent maintenance and term extensions. Several generic manufacturers (including Sandoz, Apotex, and Teva) have submitted applications to Health Canada and are preparing to launch. Source: CBC News
European Countries
Expiration Date:2031 (Core Compound) / Up to 2039 (Secondary Formulation Patents)
Status: The European landscape is protected by a dense patent thicket.
Core Molecule: While the initial 20-year patent term concluded in March 2026, Novo Nordisk successfully obtained Supplementary Protection Certificates (SPCs) across European jurisdictions. These SPCs compensate for regulatory delays and extend the monopoly on the semaglutide molecule until 2031.
Oral Formulation: Rybelsus relies on a specific absorption enhancer, SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), to survive gastric degradation and cross the gastric mucosa. Novo Nordisk holds secondary “method-of-use” and formulation patents specifically for this oral delivery mechanism that extend out to 2039. However, these secondary patents are highly vulnerable; the Boards of Appeal of the European Patent Office recently revoked two secondary patents covering the Rybelsus tablet formulation, though subsequent appeals and parallel litigations remain ongoing. Source: JUVE Patent
Knowledge Gaps & Variables
To definitively forecast exact market-entry dates for generic Rybelsus, additional data is required in two specific domains:
Regulatory Review Timelines: In Canada, the expiration of the patent does not guarantee immediate generic availability. Exact market availability relies entirely on Health Canada’s processing speed for specific generic drug submissions.
Secondary Patent Litigation: In Europe, while the core molecule is strictly locked until 2031, determining if oral semaglutide generics will be blocked from 2031 until 2039 requires continuous monitoring of European Patent Office invalidation proceedings against Novo Nordisk’s SNAC-related formulation patents. Generics manufacturers are actively attempting to “clear the way” by legally invalidating these secondary protections prior to 2031.
Sounds in the ballpark, and will get lower. You can get 300mg of grey semaglutide for about 110$ these days. That’s a little less than 3 years of supply.
Maybe they could do a generic version, if they can replicate the SNAC technology that allows for absorption. India has already been selling branded Rybelsus for years.
Started getting some quotes for the first generic brand available in India called “Sembolic”. For 10 tablets of the 14mg dose the cheapest quote I got so far was $28. The cheapest quote I got before for the same amount of Rybelsus was $40, so there’s definitely some deflation manifesting already. As it’s still early I suspect we’re gonna see further price declines over the coming weeks.
Looks like it’s available… from my checking on IndiaMart. Lots of price variation as this is a new product, so hunt around for the best price if you’re looking at this option.
Disappointingly, you have to order the dose/pill you want to use (no pill splitting)…
Rybelsus (oral semaglutide) cannot be split, crushed, or chewed without compromising its pharmacological efficacy. The tablet must be swallowed whole to retain its clinical effectiveness.
The Pharmacological Mechanism
The restriction against altering the physical integrity of the tablet is rooted in the drug’s oral delivery vector. Peptide hormones like semaglutide are naturally highly susceptible to proteolytic degradation by stomach acid and digestive enzymes, which typically renders oral administration ineffective.
To bypass this biological barrier, Rybelsus is co-formulated with an absorption enhancer known as sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The SNAC compound operates by creating a localized, transient increase in gastric pH. This neutralization of stomach acid immediately surrounding the intact tablet protects the semaglutide molecule from enzymatic destruction and facilitates its transcellular absorption across the gastric mucosa.
Consequences of Pill Splitting
Splitting or crushing the tablet disrupts the precise architectural co-formulation of SNAC and semaglutide.
Loss of Protection: Altering the pill exposes the active peptide to the harsh gastric environment before the SNAC buffering mechanism can properly deploy.
Degradation: The semaglutide is rapidly degraded by gastric enzymes.
Reduced Bioavailability: The clinical result is highly variable or a complete loss of systemic absorption, neutralizing its metabolic utility for glycemic control, weight management, and related longevity pathways.
The official FDA Prescribing Information explicitly mandates the administration protocol: “Swallow tablets whole. Do not split, crush, or chew tablets.”
This is not new, rybelsus has been available from India for some time now, probably more than 2 years.
Splitting would render the pills useless anyway because it would destroy the peptide inside of them . There is a reason you have to take the pills fasted, with very little water, and have to wait at least 30 minutes before consuming food. It’s a mediocre product overall.
It will be important to make sure any generics contain the SNAC technology, otherwise it’s the same worthless junk as compounded oral semaglutide in the USA.
Torrent Pharma has launched generic semaglutide in India under the brand names Sembolic and Semalix . These brands include both oral tablets (utilizing SNAC technology) and injectable formulations to treat type 2 diabetes and manage weight. They are priced around ₹3,999/month, offering a more accessible GLP-1 option
I’ve already taken Rybelsus so I’m happy to share my subjective impression once I get my hands on the Sembolic, so that other people can make a more informed judgement.
I only got 10 tablets of the highest dose 14mg. Although it has the special coating, I decided to still test quartering the tablets in the interest of curiosity. As expected, I did not notice much effect from the quartered tablets.
Then I proceeded to test the full tablets. I dosed it two days in a row and noticed a dramatic effect. A huge loss of interest in food, basically I stopped all snacking plus sometimes I would say I have enough during a meal which I never normally do (I always try to finish what is in front of me). Same with alcohol, when out with my friends for dinner I was happy after just one drink. I’m not a big drinker but I still noticed the effect.
Since the suppression was so strong after just 2 tablets and the halflife is around 6 days, I decided to dose once weekly for the remainder. I would take a tablet on Sunday and notice strong suppression until around Thursday. On Saturday I would tend to eat a lot as the effect weakened significantly by then. I wasn’t tracking my weight closely as I’m at a good weight (168cm ~60kg, with consistent resistance training for years), but I did notice I was starting to lean out further as the weeks went on.
I also noticed a decline in the efficacy over time. It’s possible that this was just an artifact of having taken doses two days in a row for my first time, which meant that over the period my average blood concentration would’ve been on a declining trend (owing to the long half life and lower subsequent doses). However I suspect there is at least some tolerance effect.
Once I get the generic I plan to dose twice a week and see if that is enough to keep consistent suppression, probably Sunday and Wednesday.
